Showing results (51-60 of 346) with videos related to
Sort By:
Pageof 35
Clinical and Experimental Immunology|January 1, 1979
Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populationsN Thatcher, R Swindell, D CrowtherAnnals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1997
A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group StudyH E Lambert, G J Rustin, W M Gregory, et al.British Journal of Cancer|October 1, 1992
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide productionL L Thomsen, B C Baguley, G J Rustin, et al.The Histochemical Journal|January 1, 1981
Electron microscopic cytochemical localization of nucleoside phosphatases in normal and chronic granulocytic leukaemic human neutrophilsP D Wilson, G J Rustin, G P Smith, et al.European Journal of Gynaecological Oncology|January 1, 1996
Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancerC R Lee, P W Nicholson, J A Ledermann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levelsG J Rustin, M Marples, A E Nelstrop, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group studyH E Lambert, G J Rustin, W M Gregory, et al.European Journal of Cancer & Clinical Oncology|December 1, 1989
Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreasedK S Tonkin, G J Rustin, B Wignall, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary GroupD B Smith, G J Rustin, N Howells, et al.Scandinavian Journal of Clinical and Laboratory Investigation|February 24, 2001
Biological variation and analytical imprecision of CA 125 in patients with ovarian cancerM K Tuxen, G Sölétormos, G J Rustin, et al.Pageof 35